Portfolio overview
Predictions about biotech companies, written down before the news arrives and then locked. We analyse one program at a time. A program is one drug for one disease, not the whole company. Each program has one big event that will come out as a clear yes or no (a "binary catalyst"), such as a trial result. We predict two things separately: the outcome (does the trial or the regulator say yes?) and the stock direction (does the share price go up or down around the event?). Unfamiliar words are explained in the glossary.
Data as of 2026-10-17
Companies
22
stock ticker symbols covered
Programs analysed
24
24 passed the data-coverage check
Predictions locked
24
outcome and stock
Settled
11
13 awaiting the result
Next catalyst
2026-08-26
earliest confirmed readout
Catalyst timeline
When each analysed program is expected to report its result
24 of 24 analysed programshave a confirmed readout window.
Table view (the same information as the chart, as text)
Programs by company
The chance of a good outcome and the two stock scenarios are worked out separately, each from its own named evidence, so they do not always agree
| Program | Catalyst | Data check | Outcome | Scenario prices | Expected price vs today | |
|---|---|---|---|---|---|---|
| LGVN Longeveron Inc 1 analysed program | ||||||
| Laromestrocel (Lomecel-B) Hypoplastic left heart syndrome (HLHS) — adjunct to stage-2 (Glenn) surgical palliation in infants | 2026-08-12 → 2026-10-31 confirmed readout window (expected period) | Cleared (data check passed) | Miss 30%
[20–40]
| $0.22–$0.45 $1.20–$2.20 | $0.74+0.6%
modelled estimate
-17.8% to +19.1% compared with the current price, across our 20–40% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| VALN Valneva SE 1 analysed program | ||||||
| Shigella4V2 (S4V2) Prevention of shigellosis caused by Shigella sonnei and Shigella flexneri serotypes 2a, 3a and 6 | 2026-08-13 → 2026-12-31 confirmed readout window (expected period) | Cleared (data check passed) | Miss 32%
[20–47]
| $4.60–$5.15 $5.80–$7.00 | $5.36+1.2%
modelled estimate
-2.3% to +5.5% compared with the current price, across our 20–47% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| MNOV MediciNova, Inc. 1 analysed program | ||||||
| MN-001 (tipelukast) Hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to type 2 diabetes mellitus (T2DM) | 2026-08-26 → 2026-10-31 confirmed readout window (expected period) | Cleared (data check passed) | Miss 15%
[8–28]
| $1.05–$1.50 $1.60–$2.15 | $1.37+2.6%
modelled estimate
-0.5% to +8.5% compared with the current price, across our 8–28% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| ARCT Arcturus Therapeutics Holdings Inc. 1 analysed program | ||||||
| ARCT-810 (LUNAR-OTC) Ornithine transcarbamylase (OTC) deficiency | 2026-09-01 → 2026-11-30 confirmed readout window (expected period) | Cleared (data check passed) | Miss 38%
[25–52]
| $6.00–$7.20 $9.50–$13.00 | $8.37+5.0%
modelled estimate
-2.6% to +13.1% compared with the current price, across our 25–52% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| CNTB Connect Biopharma Holdings Limited 2 analysed programs | ||||||
| Rademikibart (CBP-201) Acute exacerbations of asthma with type 2 inflammation (blood eosinophils >=300 cells/uL), in adults and adolescents aged 12-75 | 2026-09-01 → 2026-10-31 confirmed readout window (expected period) | Cleared (data check passed) | Miss 38%
[26–52]
| $0.95–$1.60 $3.60–$6.50 | $2.71+16.3%
modelled estimate
-3.2% to +39.0% compared with the current price, across our 26–52% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| Rademikibart (CBP-201) Acute exacerbations of COPD with type 2 inflammation (blood eosinophils >=300 cells/uL at the exacerbation), in adults aged 40-80, given as an add-on to standard of care | 2026-09-01 → 2026-10-31 confirmed readout window (expected period) | Cleared (data check passed) | Miss 30%
[20–42]
| $1.10–$2.10 $4.00–$7.00 | $2.77+8.2%
modelled estimate
-7.0% to +26.5% compared with the current price, across our 20–42% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| EVMN Evommune, Inc. 1 analysed program | ||||||
| EVO756 (oral MRGPRX2 antagonist) Moderate-to-severe atopic dermatitis | 2026-09-01 → 2026-09-30 confirmed readout window (expected period) | Cleared (data check passed) | Miss 30%
[20–45]
| $8.50–$11.00 $21.00–$30.00 | $14.48+1.6%
modelled estimate
-9.5% to +18.2% compared with the current price, across our 20–45% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| IRON Disc Medicine, Inc. 1 analysed program | ||||||
| DISC-3405 (formerly MWTX-003) Polycythemia vera | 2026-09-01 → 2026-10-31 confirmed readout window (expected period) | Cleared (data check passed) | Positive 78%
[65–87]
| $67.00–$74.00 $84.00–$91.00 | $83.76+5.3%
modelled estimate
+2.6% to +7.3% compared with the current price, across our 65–87% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| RARE Ultragenyx Pharmaceutical Inc. 2 analysed programs | ||||||
| DTX301 (avalotcagene ontaparvovec) Late-onset ornithine transcarbamylase (OTC) deficiency, age 12 and over | 2027-01-01 → 2027-09-30 confirmed readout window (expected period) | Cleared (data check passed) | Positive 62%
[48–75]
| $22.00–$27.00 $27.00–$33.00 | $27.91+4.6%
modelled estimate
+1.8% to +7.3% compared with the current price, across our 48–75% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| GTX-102 (apazunersen) Angelman syndrome caused by full maternal UBE3A deletion, ages 4-17 | 2026-09-01 → 2026-11-10 confirmed readout window (expected period) | Cleared (data check passed) | Uncertain 50%
[35–65]
| $16.00–$21.00 $34.00–$42.00 | $28.25+9.4%
modelled estimate
-1.9% to +20.7% compared with the current price, across our 35–65% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| TYRA Tyra Biosciences 1 analysed program | ||||||
| dabogratinib (TYRA-300) Low-grade, intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), FGFR3-altered | 2026-09-01 → 2026-10-31 confirmed readout window (expected period) | Cleared (data check passed) | Positive 55%
[40–68]
| $14.00–$20.00 $30.00–$46.00 | $28.55+5.9%
modelled estimate
-5.8% to +16.0% compared with the current price, across our 40–68% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| CUE Cue Biopharma, Inc. 1 analysed program | ||||||
| CUE-221 (formerly Ascendant-221, formerly UB-221) - humanised anti-IgE IgG1 monoclonal antibody Chronic spontaneous urticaria (long-lasting hives with no identifiable trigger), in patients inadequately controlled by H1-antihistamines | 2026-09-15 → 2026-12-15 confirmed readout window (expected period) | Cleared (data check passed) | Positive 72%
[58–83]
| $9.00–$16.00 $24.00–$46.00 | $28.70+10.0%
modelled estimate
-2.1% to +19.4% compared with the current price, across our 58–83% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| TLSA Tiziana Life Sciences 1 analysed program | ||||||
| intranasal foralumab (TZLS-401 / NI-0401) Non-active secondary progressive multiple sclerosis (na-SPMS) | 2026-09-15 → 2026-11-30 confirmed readout window (expected period) | Cleared (data check passed) | Miss 35%
[20–52]
| $0.30–$0.55 $1.80–$3.00 | $1.12+11.6%
modelled estimate
-18.0% to +45.2% compared with the current price, across our 20–52% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| CGEM Cullinan Therapeutics, Inc. 1 analysed program | ||||||
| Zipalertinib (CLN-081 / TAS-6417) Previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer carrying an EGFR exon 20 insertion mutation (first line) | 2026-10-01 → 2027-03-31 confirmed readout window (expected period) | Cleared (data check passed) | Positive 78%
[65–88]
| $13.50–$16.25 $19.50–$24.00 | $20.24+12.2%
modelled estimate
+7.3% to +16.1% compared with the current price, across our 65–88% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| DWTX Dogwood Therapeutics, Inc. 1 analysed program | ||||||
| Halneuron (purified tetrodotoxin) Chemotherapy-induced neuropathic pain (CINP) attributable to prior platinum and/or taxane chemotherapy | 2026-10-01 → 2026-12-31 confirmed readout window (expected period) | Cleared (data check passed) | Miss 38%
[26–49]
| $0.28–$1.28 $3.28–$9.50 | $2.91+50.5%
modelled estimate
+15.7% to +82.4% compared with the current price, across our 26–49% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| GNLX Genelux Corporation 1 analysed program | ||||||
| Olvi-Vec (olvimulogene nanivacirepvec), also known as GL-ONC1 and GLV-1h68, an engineered oncolytic vaccinia virus, given intraperitoneally and followed by platinum-doublet chemotherapy plus bevacizumab Platinum-resistant or platinum-refractory, non-resectable high-grade serous, endometrioid or clear-cell ovarian, fallopian tube or primary peritoneal cancer, after at least three prior lines of systemic therapy including bevacizumab | 2026-10-01 → 2027-04-30 confirmed readout window (expected period) | Cleared (data check passed) | Uncertain 35%
[20–55]
| $0.45–$1.30 $6.00–$14.00 | $4.07+49.6%
modelled estimate
-0.7% to +116.7% compared with the current price, across our 20–55% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| IVA Inventiva S.A. 1 analysed program | ||||||
| lanifibranor (IVA337) Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis stage F2 or F3 | 2026-10-01 → 2026-12-31 confirmed readout window (expected period) | Cleared (data check passed) | Positive 55%
[40–70]
| $1.00–$2.00 $7.00–$13.00 | $6.18+30.9%
modelled estimate
+3.8% to +57.8% compared with the current price, across our 40–70% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| RAPP Rapport Therapeutics, Inc. 1 analysed program | ||||||
| RAP-219 Acute treatment of manic episodes, with or without mixed features, associated with bipolar I disorder, in adults aged 18-65 | 2026-10-01 → 2026-11-30 confirmed readout window (expected period) | Cleared (data check passed) | Miss 35%
[22–48]
| $37.00–$45.00 $56.00–$68.00 | $48.35-1.2%
modelled estimate
-6.8% to +4.4% compared with the current price, across our 22–48% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| IMMP Immutep Limited 1 analysed program | ||||||
| Eftilagimod alfa (efti, IMP321) with pembrolizumab and radiotherapy Resectable, non-metastatic, FNCLCC grade 2-3 soft tissue sarcoma of the extremities, girdles or superficial trunk, primary tumour larger than 5 cm or any locally recurrent tumour, given before surgery | 2026-10-19 → 2026-10-19 confirmed readout window (expected period) | Cleared (data check passed) | Positive 85%
[72–92]
| $2.30–$3.00 $3.05–$4.00 | $3.39+6.1%
modelled estimate
+2.5% to +8.0% compared with the current price, across our 72–92% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| CMPX Compass Therapeutics, Inc. 1 analysed program | ||||||
| Tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody Second-line unresectable advanced, metastatic or recurrent biliary tract cancer | 2026-10-23 → 2026-10-27 confirmed readout window (expected period) | Cleared (data check passed) | Uncertain 45%
[32–58]
| $0.62–$0.84 $0.87–$1.15 | $0.86-0.5%
modelled estimate
-4.7% to +3.8% compared with the current price, across our 32–58% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| ABOS Acumen Pharmaceuticals 1 analysed program | ||||||
| sabirnetug (ACU193) Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia, amyloid-confirmed) | 2026-11-15 → 2027-01-31 confirmed readout window (expected period) | Cleared (data check passed) | Miss 35%
[25–48]
| $0.55–$1.20 $4.50–$11.00 | $3.28+43.9%
modelled estimate
+13.8% to +83.1% compared with the current price, across our 25–48% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| IMUX Immunic, Inc. 1 analysed program | ||||||
| vidofludimus calcium (IMU-838) Relapsing multiple sclerosis (relapsing-remitting and active secondary progressive) | 2026-12-01 → 2027-03-31 confirmed readout window (expected period) | Cleared (data check passed) | Positive 60%
[50–70]
| $2.40–$3.80 $17.00–$27.00 | $14.44+2.4%
modelled estimate
-11.0% to +15.8% compared with the current price, across our 50–70% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| OLMA Olema Pharmaceuticals 1 analysed program | ||||||
| palazestrant (OP-1250) ER+/HER2- locally advanced or metastatic breast cancer, second and third line, after endocrine therapy plus a CDK4/6 inhibitor | 2027-01-01 → 2027-06-30 confirmed readout window (expected period) | Cleared (data check passed) | Uncertain 40%
[30–52]
| $4.50–$8.50 $15.50–$32.00 | $13.40+28.5%
modelled estimate
+11.9% to +48.3% compared with the current price, across our 30–52% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
| ZNTL Zentalis Pharmaceuticals 1 analysed program | ||||||
| azenosertib (ZN-c3) Cyclin E1-positive platinum-resistant ovarian cancer (PROC) | 2027-01-01 → 2027-06-30 confirmed readout window (expected period) | Cleared (data check passed) | Positive 55%
[42–68]
| $1.00–$2.30 $6.50–$10.00 | $5.28+26.9%
modelled estimate
+6.3% to +47.5% compared with the current price, across our 42–68% range of probabilities. We cannot tell yet whether it is above or below the current price. | |
Run-up priority ranking
A 0 to 100 score for each program, built from seven factors, and the test result on whether the score can be trusted yet
A "run-up" is a rise in a company's share price in the weeks before its trial result comes out.
This table gives each analysed program a run-up priority score from 0 to 100 (formula
v2.0.0, in lib/runup.mjs).
The score is worked out fresh on every build. It does not read the list of locked predictions,
so it is separate from the run-up calls already locked there. One part of the score,
value_uplift, still uses the
pre-2.0.0 method on this page. It needs an input called
ratio_base that is not supplied yet.
The 6.0.0 entry in CHANGELOG.md notes the same gap for the backtest.
So the version label does not mean these numbers differ from 1.0.0's. The rows are ordered by when the
readout window opens (the same earliest-date order as the table above),
not by this score.
Score verdict: FAILING (in the test, the score did no better than chance at telling programs apart)
A backtest checks a score against past price moves.
scripts/runup-backtest.mjs compared
priority_score with real trading history
for 141 of 144 rows (each row is one program on one past date).
The measure is rho, a number from -1 to +1 that shows how well the score's ranking matches the ranking
of the actual price rises. Higher is better, and 0 means no link at all.
The pooled rho is -0.02. The pass mark was
0.3, and we set it before looking at any
data. Unrounded, the pooled rho is -0.022.
Computed within each past date, it averages -0.055
(range -0.25 to +0.335).
A simple baseline that ranks by catalyst date scores
0.009, so the score is not better than that either.
Only two of the seven drivers below vary in this data: how much is already
priced in, and how easily the stock trades (part of "squeeze").
An earlier run (2026-08-06, formula 1.0.0) scored 0.257 and was judged INCONCLUSIVE.
The rows below are ordered by the readout window and not by this score.
Driver detail table (all seven driver scores for each program)
| Program | UN | VU | OP | DC | SQ | PI | FC |
|---|---|---|---|---|---|---|---|
| LGVN/laromestrocel-hlhs | 50 | 50 | 50 | 10 | 65 | 100 | 45 |
| VALN/s4v2-shigellosis | 50 | 50 | 50 | 10 | 65 | 88 | 45 |
| MNOV/mn-001-nafld-hypertriglyceridemia | 50 | 50 | 50 | 10 | 65 | 91 | 45 |
| ARCT/arct-810-otc-deficiency | 50 | 50 | 50 | 10 | 50 | 74 | 45 |
| CNTB/rademikibart-acute-asthma-exacerbation | 50 | 50 | 50 | 10 | 58 | 98 | 45 |
| CNTB/rademikibart-acute-copd-exacerbation | 50 | 50 | 50 | 10 | 58 | 98 | 45 |
| EVMN/evo756-atopic-dermatitis | 50 | 50 | 50 | 10 | 58 | 100 | 45 |
| IRON/disc-3405-polycythemia-vera | 50 | 50 | 50 | 10 | 43 | 72 | 45 |
| RARE/gtx-102-angelman-syndrome | 50 | 50 | 50 | 10 | 43 | 93 | 45 |
| TYRA/dabogratinib-ir-nmibc | 50 | 50 | 50 | 10 | 50 | 81 | 45 |
| CUE/cue-221-csu | 50 | 50 | 50 | 10 | 50 | 71 | 45 |
| TLSA/foralumab-na-spms | 50 | 50 | 50 | 10 | 65 | 78 | 45 |
| CGEM/zipalertinib-1l-egfr-ex20ins-nsclc | 50 | 50 | 50 | 10 | 50 | 62 | 45 |
| DWTX/halneuron-cinp | 50 | 50 | 50 | 10 | 65 | 99 | 45 |
| GNLX/olvi-vec-platinum-resistant-ovarian | 50 | 50 | 50 | 10 | 65 | 98 | 45 |
| IVA/lanifibranor-mash | 50 | 50 | 50 | 10 | 58 | 98 | 45 |
| RAPP/rap-219-bipolar-mania | 50 | 50 | 50 | 10 | 50 | 87 | 45 |
| IMMP/efti-pembrolizumab-soft-tissue-sarcoma | 50 | 50 | 50 | 40 | 65 | 100 | 45 |
| CMPX/tovecimig-biliary-tract-cancer | 50 | 50 | 50 | 40 | 58 | 99 | 45 |
| ABOS/sabirnetug-alzheimers | 50 | 50 | 50 | 10 | 65 | 91 | 45 |
| IMUX/vidofludimus-relapsing-ms | 50 | 50 | 50 | 10 | 58 | 85 | 45 |
| OLMA/palazestrant-er-positive-mbc | 50 | 50 | 50 | 10 | 50 | 100 | 45 |
| RARE/dtx301-otc-deficiency | 50 | 50 | 50 | 10 | 43 | 93 | 45 |
| ZNTL/azenosertib-cyclin-e1-proc | 50 | 50 | 50 | 10 | 58 | 84 | 45 |
Unmet need, value uplift and outcome probability all score a neutral 50. No run-up call has ever been locked, so there is no analyst judgement to read. Using today's real outcome probability would use knowledge from after the date being scored, so it is not used here. Date confidence is a stand-in based on whether BPIQ (the biotech data service we use) gives an exact day. It is low for every program. Financing/clustering risk uses a default value when no stored attribution or cash-runway call exists. Hover over a priced-in or squeeze number above to see how it was worked out.